" data-index="1" alt="Go to Introduction
" onclick="event.preventDefault();document.getElementsByTagName('h2')[(1 - 1)].scrollIntoView({behavior: 'smooth',block: 'start'});">Introduction
" data-index="2" alt="Go to Medication for candida and dermatophyte infections (azoles)
" onclick="event.preventDefault();document.getElementsByTagName('h2')[(2 - 1)].scrollIntoView({behavior: 'smooth',block: 'start'});">Medication for candida and dermatophyte infections (azoles)
" data-index="3" alt="Go to Medications only for candida infections
" onclick="event.preventDefault();document.getElementsByTagName('h2')[(3 - 1)].scrollIntoView({behavior: 'smooth',block: 'start'});">Medications only for candida infections
" data-index="4" alt="Go to Medications only for dermatophyte infections
" onclick="event.preventDefault();document.getElementsByTagName('h2')[(4 - 1)].scrollIntoView({behavior: 'smooth',block: 'start'});">Medications only for dermatophyte infections
Antifungal drug resistance
Oral antifungal medications may be required for fungal infection if:
The choice of oral antifungal medication, its dose and the duration of treatment depend on:
The trade names of the medications sold in New Zealand are given in parentheses.
Voriconazole (Vfend® tablets) and posaconazole are reserved for serious invasive Candida and mould infections.
Some species of candida are resistant to azoles, and azole resistance is increasing especially in immunosuppressed patients who are prescribed long courses.
In recent years, both topical and oral allylamine and triazole antifungal drug resistance has become a problem, particularly in the Indian subcontinent.
Extensive therapy-resistant dermatophyte infection should prompt this as a possible problem. Where available, fungal culture and estimation of drug minimum inhibitory concentration determined to guide appropriate medication
For more information, see antifungal drug resistance.
Approved datasheets are the official source of information for medicines, including approved uses, doses, and safety information. Check the individual datasheet in your country for information about medicines.
We suggest you refer to your national drug approval agency such as the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA), UK Medicines and Healthcare products regulatory agency (MHRA) / emc, and NZ Medsafe, or a national or state-approved formulary eg, the New Zealand Formulary (NZF) and New Zealand Formulary for Children (NZFC) and the British National Formulary (BNF) and British National Formulary for Children(BNFC).
